What were once hot health care commodities during the pandemic are now laggards as both Remdesivir (Gilead) and Tocilizumab (Roche) barely see shelf movement despite the latest raging wave of the pandemic. Earlier on in pandemic, the well-to-do in India would literally pawn off assets to secure product supply for fear of getting sick without. But now that the second COVID-19 pandemic wave ebbs, and perhaps as other more economical drugs showed their worth, from Favipiravir to yes, even ivermectin, the reality here is that pandemic economics rapidly change even as companies such as Merck make big plays for their somewhat “Me Too” pandemic product for ambulatory cases. But the stagnation in product movement is so great now pharmacists here suggest much of the inventory risks expiry unless a third wave occurs. Moreover, antifungal drug demand diminishes given the fall in overall mucormycosis cases.
Apparently, some generic companies Gilead lined up are ceasing production because the demand is so low. For example, the Times of India reports that Genetek Lifesciences Private Limited ceased production of remdesivir, although they are ready to produce should the market demand return.
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).